Policymakers and drugmakers are rethinking how medicines move around the world, but reversing decades of globalization is proving slow and complicated. Governments want more local production after pandemic-era shortages, while companies face cost pressures, new rules, and fragile supply chains. The push to rebalance where drugs are invented, made, and shipped is colliding with financial and technical realities.
At issue is who makes key ingredients, where factories sit, and how prices are set. The stakes are high. Patients want steady access to affordable treatments. Companies need stable returns to fund research. Leaders in the United States, Europe, and Asia are weighing subsidies, procurement changes, and stockpile mandates to reduce future shocks.
“Unpicking pharma’s globalised business model is harder than it looks.”
How Pharma Became So Interlinked
Over the past 30 years, drug production spread across continents. Companies concentrated manufacturing of active pharmaceutical ingredients in a few hubs, often in India and China. Final dosage forms are made in many countries, then shipped worldwide. Clinical trials recruit patients across regions to speed results and cut costs.
This system lowered prices for many generics and improved efficiency. It also added risk. Factory shutdowns, export limits, and transport delays can ripple across borders. The pandemic exposed those weak points. Hospitals faced shortages of common drugs. Regulators issued alerts on low supplies and asked firms to diversify sources.
Supply Chains Are Hard to Rebuild
Relocating production takes years, not months. Building a facility for sterile injectables or biologics requires strict standards, skilled staff, and steady utilities. Approval from regulators adds more time. Companies must also qualify new suppliers and run validation batches.
Costs are a major hurdle. Energy, labor, and compliance can be higher in new sites. For low-margin generics, even small increases can make a plant uneconomic. Buyers still tend to award contracts on price, which discourages redundancy.
- Key ingredients are concentrated among a small pool of suppliers.
- Quality failures at one site can shut off global volumes.
- Shipping delays push firms to carry larger inventories.
Policy Pressure Meets Market Reality
Governments are trying to nudge change. Some offer subsidies or tax credits for domestic plants. Others adjust procurement to reward reliability, not just price. Stockpile programs are growing, though they tie up cash and need rotation to avoid waste.
Price rules can clash with resilience goals. Caps on reimbursement may keep costs low for patients, but they also limit funds for new capacity. In the United States, recent changes to how Medicare pays for some drugs have sharpened that debate. In Europe, health systems seek savings while also calling for more local production. Companies argue they need clearer, long-term signals to invest.
R&D and Clinical Trials Face Shifts Too
Drug research has global roots. Trials often run in dozens of countries to find diverse patients and meet enrollment targets. Stricter data rules and rising costs are pushing sponsors to rethink trial footprints. Remote monitoring and digital tools can help, but they do not replace sites and staff.
If regions pull back from cross-border studies, timelines could lengthen. That would raise costs and delay access. Regulators are exploring mutual recognition and shared inspections to ease the strain without lowering standards.
Winners, Losers, and What Could Change
Large firms with cash and broad portfolios can rework supply chains more easily. Smaller manufacturers may struggle. Generic injectables and antibiotics remain vulnerable because margins are thin and demand spikes are hard to predict.
Some steps could improve reliability without sharp price jumps. Multi-sourcing critical ingredients reduces single-point failures. More transparent shortage reporting lets buyers adjust earlier. Contracts that pay for capacity, not just volume delivered, can support backup lines.
Signals To Watch
The next year will test whether policy and investment match the rhetoric. Key indicators include:
- Announcements of new facilities for APIs and sterile products.
- Changes in public tenders that reward supply security.
- Trends in shortage alerts from major regulators.
- Adoption of advanced manufacturing like continuous processing.
Industry leaders agree the old model needs reinforcement but warn against quick fixes. Moving production closer to patients can cut some risks, yet it cannot happen overnight. A blended approach—diversifying suppliers, adding regional capacity, and rewarding reliability—appears the most practical path.
The core trade-off is clear. Health systems want lower costs and steadier supply at the same time. Companies want predictable demand and fair returns for building redundancy. The coming policy choices will decide how far the system shifts and how quickly. Patients will feel the outcome first, at the pharmacy counter and in hospital wards.
